| Symbol | ETON |
|---|---|
| Name | ETON PHARMACEUTICALS, INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Address | 21925 WEST FIELD PARKWAY,SUITE 235, DEER PARK, Illinois, 60010-7278, United States |
| Telephone | +1 847 787-7361 |
| Fax | — |
| — | |
| Website | https://www.etonpharma.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001710340 |
| Description | Eton Pharmaceuticals Inc is a United States based specialty pharmaceutical company. The company is engaged in developing and commercializing pharmaceutical products to fulfill an unmet patient need. It has a diversified pipeline of around eleven product candidates in various stages of development. Additional info from NASDAQ: |
Eton Pharmaceuticals relaunches HEMANGEOL® (propranolol) Oral Solution with Eton Cares and Exclusive Specialty Pharmacy Distribution
Read more(10% Negative) ETON PHARMACEUTICALS, INC. (ETON) Announces Delay in study Trials for rare diseases Due to Regulatory Process, Safety Review, Efficacy Assessment
Read moreEton Pharmaceuticals Announces Initiation of Clinical Study for Product Candidate ET-700
Read moreNew Form DEF 14A - Eton Pharmaceuticals, Inc. <b>Filed:</b> 2026-04-24 <b>AccNo:</b> 0001437749-26-013313 <b>Size:</b> 2 MB
Read moreDirector RIEDEL NORBERT G 🟡 adjusted position in 0 shares (2 derivative) of Eton Pharmaceuticals, Inc. (ETON) at $8.61 Transaction Date: Apr 21, 2026 | Filing ID: 013041
Read more(99% Neutral) ETON PHARMACEUTICALS, INC. (ETON) Announces Business Combination
Read moreNew Form SCHEDULE 13G/A - Eton Pharmaceuticals, Inc. <b>Filed:</b> 2026-03-26 <b>AccNo:</b> 0000102909-26-001214 <b>Size:</b> 7 KB
Read more(30% Negative) ETON PHARMACEUTICALS, INC. (ETON) Reports Q1 2026 Financial Results
Read more| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| TRC093 recombinant humanized IgG1k monoclonal antibody | DRUG | Phase PHASE1 | Cancer | COMPLETED | NCT00492830 |
| TRC102 + pemetrexed | DRUG | Phase PHASE1 | Neoplasm | COMPLETED | NCT00692159 |
| TRC105 chimeric anti-CD105 antibody | DRUG | Phase PHASE1 | Cancer | COMPLETED | NCT00582985 |
| Tiotropium | DRUG | Phase PHASE2 | Asthma | COMPLETED | NCT02382510 |
| Placebo | DRUG | Phase PHASE1 | Chronic Obstructive Pulmonary Disease | COMPLETED | NCT02133339 |
| TRN-157 | DRUG | Phase PHASE1 | Chronic Obstructive Pulmonary Disease | COMPLETED | NCT02133339 |
| TRC105 and Bevacizumab | DRUG | Phase PHASE1 | Adult Solid Tumor | COMPLETED | NCT01332721 |
| Capecitabine | DRUG | Phase PHASE1 | Metastatic Breast Cancer | COMPLETED | NCT01326481 |
| Bevacizumab | BIOLOGICAL | Phase PHASE2 | Choriocarcinoma | COMPLETED | NCT02396511 |
| Votrient | DRUG | Phase PHASE3 | Advanced Angiosarcoma | COMPLETED | NCT02979899 |
| TRC105 and Pazopanib | DRUG | Phase PHASE1 | Advanced Soft Tissue Sarcoma | COMPLETED | NCT01975519 |
| OPDIVO | DRUG | Phase PHASE1 | Carcinoma, Non-Small-Cell Lung | COMPLETED | NCT03181308 |
| Sorafenib | DRUG | Phase PHASE1 | Hepatocellular Carcinoma | COMPLETED | NCT02560779 |
| Carotuximab (TRC105) | DRUG | Phase PHASE1 | Carcinoma, Non-Small-Cell Lung | COMPLETED | NCT03181308 |
| Axitinib | DRUG | Phase PHASE1 | Renal Cell Carcinoma | TERMINATED | NCT01806064 |
| TRC105 and Axitinib | DRUG | Phase PHASE1 | Renal Cell Carcinoma | TERMINATED | NCT01806064 |
| TRC253 | DRUG | Phase PHASE1 | Metastatic Castrate-resistant Prostate Cancer | COMPLETED | NCT02987829 |
| TRC105 | DRUG | Phase PHASE1 | Metastatic Breast Cancer | COMPLETED | NCT01326481 |
| Atezolizumab | DRUG | Phase PHASE1 | Solid Tumor | UNKNOWN | NCT03835949 |
| TJ004309 | DRUG | Phase PHASE1 | Solid Tumor | UNKNOWN | NCT03835949 |
| Cemiplimab | BIOLOGICAL | Phase PHASE1 | Oncology | COMPLETED | NCT05259696 |
| E-602 | BIOLOGICAL | Phase PHASE1 | Oncology | COMPLETED | NCT05259696 |
| Matching placebo control | DRUG | Phase PHASE2 | Uncontrolled Hypertension | RECRUITING | NCT07142356 |
| RTN-001 | DRUG | Phase PHASE2 | Uncontrolled Hypertension | RECRUITING | NCT07142356 |